MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2026.128424

Медицинская библиотека · Vaccine · 2026

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Rooyakkers Adora, Ye Lingyun, Cahn Pedro E, Ruiz-Palacios Guillermo M, Ikram Aamer, Lanas Fernando, Navarro Sergio Raúl Muñoz, Sued Omar, Lioznov Dmitry A, Dzutseva Vitalina, Parveen Ghazala, Zubkova Tatyana, Li Jingxin, Langley Joanne M, Wang Ruijie, Barreto Luis, Gou Jinbo, Zhu Tao, Whittle Carrie A, Halperin Scott A, CanSino COVID-19 Global Efficacy Study Group

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

BACKGROUND

An international, double-blind, placebo-controlled phase 3 study in healthy adults previously showed one dose of the Ad5-nCoV vaccine was efficacious (57.5%) against symptomatic COVID-19 infection, especially severe disease, was safe, and immunogenic (ClinicalTrials.gov, NCT04526990). The current study extends that report to assess relative vaccine efficacy (rVE), safety, and immunogenicity of two doses versus one dose of Ad5-nCoV vaccine.

METHODS

Participants from the prior (part-one) study who continued to the follow-up study (part-two) herein were provided an Ad5-nCoV dose at study sites in Argentina, Chile, Mexico, Pakistan, and Russia, starting June 8th 2021 (median = 6 months post-first-injection). This injection led to two doses and one dose received by the prior vaccine and placebo recipients, respectively. Participants were monitored for COVID-19 disease, safety, and antibody responses up to 24 weeks post-vaccination.

RESULTS

The endpoint of 83 cases occurred August 9, 2021, triggering primary efficacy analysis which evaluated rVE ≥10% (two versus one dose) of Ad5-nCoV in preventing PCR-confirmed COVID-19 disease at least 28 days post-vaccination. rVE (34.12%) was non-significant (95% CI -1.31 to 57.15, n = 8266), indicating similar efficacy of dose groups. End-of-study analysis (cutoff January 28, 2022) showed rVE was 6.3% (95% CI -8.7 to 19.2, starting 28 days), and for severe disease was 79.5% (95% CI 28.1% to 94.2%, starting 28 days). Serious adverse events (SAEs, ≥grade 4) were more frequent after one dose (12 [0.12%]) than two doses (4 [0.04%], p = 0.043), as were medically attended adverse events (9 [0.090%] and 1 [0.009%], p = 0.009). One SAE (myocarditis) was related to the study-product. Spike-RBD IgG and neutralization antibody titers were elevated for two-dose versus one-dose recipients (1.7- and 4.4-fold) at 28-days post-vaccination. Antibody responses waned by 24 weeks.

CONCLUSION

Two doses and one dose of Ad5-nCoV vaccine are efficacious, safe and immunogenic. A second dose improves protection against severe disease and immunogenicity.

TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (NCT04526990).

Для цитирования: Rooyakkers Adora, Ye Lingyun, Cahn Pedro E, Ruiz-Palacios Guillermo M, Ikram Aamer, Lanas Fernando, Navarro Sergio Raúl Muñoz, Sued Omar, Lioznov Dmitry A, Dzutseva Vitalina, Parveen Ghazala, Zubkova Tatyana, Li Jingxin, Langley Joanne M, Wang Ruijie, Barreto Luis, Gou Jinbo, Zhu Tao, Whittle Carrie A, Halperin Scott A, CanSino COVID-19 Global Efficacy Study Group. Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.. Vaccine. 2026. DOI: 10.1016/j.vaccine.2026.128424.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.